JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers):
holder breadth -9.5% ·
share flow -2.2% ·
net new positions -10.5%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 12.70M | $3.29B | n/a | −2 |
| Q2 2026 | 181 | +1 | 1.42B | $361.32B | +5 | −5 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | n/a | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | n/a |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | n/a | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | n/a |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | n/a | −2 |
| Q2 2024 | 21 | n/a | 161.11M | $23.53B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 56.11M | +1.8% | $9.06B | 0.7% | ▲ Add | 2 | SEC ↗ ×2 |
| 2 | Norges Bank ✦ (passive) | 29.04M | -0.2% | $4.71B | 0.7% | ▼ Trim | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 25.16M | +1.0% | $4.08B | 0.5% | ▲ Add | 2 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 23.93M | -3.7% | $3.88B | 0.7% | ▼ Trim | 2 | SEC ↗ ×7 |
| 5 | Fisher Asset Management ✦ | 7.56M | +7.9% | $1.23B | 0.5% | ▲ Add | 2 | SEC ↗ |
| 6 | Marshall Wace ✦ | 5.27M | +35.7% | $854.30M | 1.1% | ▲ Add | 2 | SEC ↗ ×3 |
| 7 | AQR Capital Management ✦ | 3.16M | -5.7% | $509.92M | 0.7% | ▼ Trim | 2 | SEC ↗ ×5 |
| 8 | Adage Capital Partners ✦ | 1.62M | +89.9% | $262.40M | 0.5% | ▲ Add | 2 | SEC ↗ |
| 9 | Bridgewater Associates ✦ | 1.47M | -54.1% | $238.25M | 1.3% | ▼ Trim | 2 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 1.15M | +39.2% | $186.83M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 11 | Tweedy, Browne ✦ | 1.13M | -0.4% | $182.51M | 8.7% | ▼ Trim | 2 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 657.80K | -54.8% | $106.60M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 13 | Markel Group ✦ | 610.80K | 0.0% | $98.99M | 0.9% | Held | 2 | SEC ↗ ×2 |
| 14 | Gotham Asset Management ✦ | 217.64K | -0.2% | $35.27M | 0.4% | ▼ Trim | 2 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 204.36K | -82.4% | $33.12M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 16 | GAMCO Investors ✦ | 96.58K | -1.8% | $15.65M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 17 | Millennium Management ✦ | 81.37K | -92.4% | $13.19M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Fairfax Financial ✦ | 73.40K | 0.0% | $11.89M | 1.1% | Held | 2 | SEC ↗ |
| 19 | Dodge & Cox ✦ | 21.10K | 0.0% | $3.42M | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $223.58M | was 0.4% |
| Two Sigma Investments | $94.97M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 136.10K shares, $33,268 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 11.07K sh · $3.04M
Officer · 22.53K sh · $6.19M
Officer · 15.00K sh · $3.95M
Officer, Director · 102.31K sh · $26.70M
Officer, Director · 20.98K sh · $5.50M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology